PARP-1 regulates inflammasome activity by poly-ADP-ribosylation of NLRP3 and interaction with TXNIP in primary macrophages

被引:0
作者
Ling-Ya Chiu
Duen-Yi Huang
Wan-Wan Lin
机构
[1] National Taiwan University,Department of Pharmacology, College of Medicine
[2] National Defense Medical Center,Department and Graduate Institute of Pharmacology
[3] Taipei Medical University,Graduate Institute of Medical Sciences
来源
Cellular and Molecular Life Sciences | 2022年 / 79卷
关键词
PARP-1; Inflammasome; TXNIP; NLRP3; ROS;
D O I
暂无
中图分类号
学科分类号
摘要
Poly(ADP-ribose) polymerase-1 (PARP-1) plays an essential role in DNA repair by catalyzing the polymerization of ADP-ribose unit to target proteins. Several studies have shown that PARP-1 can regulate inflammatory responses in various disease models. The intracellular Nod-like receptor NLRP3 has emerged as the most crucial innate immune receptor because of its broad specificity in mediating immune response to pathogen invasion and danger signals associated with cellular damage. In our study, we found NLRP3 stimuli-induced caspase-1 maturation and IL-1β production were impaired by PARP-1 knockout or PARP-1 inhibition in bone marrow-derived macrophages (BMDM). The step 1 signal of NLRP3 inflammasome activation was not affected by PARP-1 deficiency. Moreover, ATP-induced cytosolic ROS production was lower in Parp-1−/− BMDM, resulting in the decreased inflammasome complex assembly. PARP-1 can translocate to cytosol upon ATP stimulation and trigger the PARylation modification on NLRP3, leading to NLRP3 inflammasome assembly. PARP-1 was also a bridge between NLRP3 and thioredoxin-interacting protein (TXNIP) and participated in NLRP3/TXNIP complex formation for inflammasome activation. Overall, PARP-1 positively regulates NLRP3 inflammasome activation via increasing ROS production and interaction with TXNIP and NLRP3, leading to PARylation of NLRP3. Our data demonstrate a novel regulatory mechanism for NLRP3 inflammasome activation by PARP-1. Therefore, PARP-1 can serve as a potential target in the treatment of IL-1β associated inflammatory diseases.
引用
收藏
相关论文
共 280 条
  • [1] Hottiger MO(2010)Toward a unified nomenclature for mammalian ADP-ribosyltransferases Trends Biochem Sci 35 208-219
  • [2] Hassa PO(2017)The multifaceted roles of PARP1 in DNA repair and chromatin remodelling Nat Rev Mol Cell Biol 18 610-621
  • [3] Luscher B(2019)Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins Nucleic Acids Res 47 3811-3827
  • [4] Schuler H(2020)Poly(ADP-ribose) polymerase inhibition: past, present and future Nat Rev Drug Discov 19 711-736
  • [5] Koch-Nolte F(2009)Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos) J Neurochem 110 687-696
  • [6] Ray Chaudhuri A(2020)The histone variant MacroH2A1 regulates key genes for myogenic cell fusion in a splice-isoform dependent manner Cells 12 651-6725
  • [7] Nussenzweig A(2021)Parp mutations protect from mitochondrial toxicity in Alzheimer's disease Cell Death Dis 78 6717-364
  • [8] Alemasova EE(2018)Development of PARP and immune-checkpoint inhibitor combinations Cancer Res 27 359-194
  • [9] Lavrik OI(2009)A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial J Thromb Thrombolysis 82 176-29
  • [10] Curtin NJ(2019)Multifaceted role of PARP-1 in DNA repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases Cells 353 1-832